Search research articles
Contact Us
Filters
Showing results (251-260 of 362) with videos related to
Page
of 37
Sort By:
Revue Medicale Suisse
|
February 2, 2022
[2021 Oncology update]
May-Lucie Meyer, Konstantina Chrysou, Antonia Stamatiou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 24, 2026
Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743
Arnaud Scherpereel, Paul Baas, Anna K Nowak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 2, 2026
Erratum: Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743
Arnaud Scherpereel, Paul Baas, Anna K Nowak, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 6, 2022
A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial
Giuseppe Luigi Banna, Alfredo Addeo, Panagiota Zygoura, et al.
The Lancet. Oncology
|
September 15, 2022
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
Mary O'Brien, Luis Paz-Ares, Sandrine Marreaud, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 3, 2022
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study
Melissa L Johnson, Byoung Chul Cho, Alexander Luft, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 30, 2018
Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01)
Martin Früh, Daniel C Betticher, Roger Stupp, et al.
Cancer Immunology, Immunotherapy : CII
|
June 14, 2021
Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma
Jan Budczies, Martina Kirchner, Klaus Kluck, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 29, 2025
ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC
Sabine Schmid, Georgia Dimopoulou, Paul van Schil, et al.
Clinical Lung Cancer
|
April 7, 2015
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09
Oliver Gautschi, Nicholas Mach, Sacha I Rothschild, et al.
Page
of 37
Search research articles
Search
Showing results (251-260 of 362) with videos related to
Sort By:
Page
of 37
Revue Medicale Suisse
|
February 2, 2022
[2021 Oncology update]
May-Lucie Meyer, Konstantina Chrysou, Antonia Stamatiou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 24, 2026
Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743
Arnaud Scherpereel, Paul Baas, Anna K Nowak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 2, 2026
Erratum: Five-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743
Arnaud Scherpereel, Paul Baas, Anna K Nowak, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 6, 2022
A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial
Giuseppe Luigi Banna, Alfredo Addeo, Panagiota Zygoura, et al.
The Lancet. Oncology
|
September 15, 2022
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
Mary O'Brien, Luis Paz-Ares, Sandrine Marreaud, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 3, 2022
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study
Melissa L Johnson, Byoung Chul Cho, Alexander Luft, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
September 30, 2018
Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01)
Martin Früh, Daniel C Betticher, Roger Stupp, et al.
Cancer Immunology, Immunotherapy : CII
|
June 14, 2021
Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma
Jan Budczies, Martina Kirchner, Klaus Kluck, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 29, 2025
ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC
Sabine Schmid, Georgia Dimopoulou, Paul van Schil, et al.
Clinical Lung Cancer
|
April 7, 2015
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09
Oliver Gautschi, Nicholas Mach, Sacha I Rothschild, et al.
Page
of 37